Grunenthal nabs AstraZeneca exec as new CEO

7 June 2016

German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016.

Mr Baertschi will join Grünenthal from Anglo-Swedish pharma major AstraZeneca (LSE: AZN), where he currently serves as country president for Japan.

A native of Switzerland, Mr Baertschi has more than 17 years of international experience in the pharmaceutical industry, including the last three years as country president for Japan when he was responsible for an organization of over $3 billion in sales and over 3,000 employees across R&D, manufacturing and commercial functions. Under Mr Baertschi tenure, AstraZeneca moved from the 12th to the 6th best-selling pharma company in Japan, and significantly shortened drug development timelines. Prior to taking up his current role in 2013, he served as country president for Germany and earlier in his career served as country manager in various Emerging Markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK